Drug Type Monoclonal antibody |
Synonyms B-3 (Meiji Seika Pharma/Juntendo University) |
Target |
Mechanism CALR modulators(calreticulin modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myeloproliferative Disorders | Preclinical | JP | - | |
Myeloproliferative Disorders | Preclinical | JP | - | |
Myeloproliferative Disorders | Preclinical | JP | - | |
Myeloproliferative Disorders | Preclinical | JP | - | |
Myeloproliferative Disorders | Preclinical | JP | - |